Details for New Drug Application (NDA): 217549
✉ Email this page to a colleague
NDA 217549 describes SODIUM ZIRCONIUM CYCLOSILICATE, which is a drug marketed by Lupin and is included in one NDA. Additional details are available on the SODIUM ZIRCONIUM CYCLOSILICATE profile page.
The generic ingredient in SODIUM ZIRCONIUM CYCLOSILICATE is sodium zirconium cyclosilicate. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the sodium zirconium cyclosilicate profile page.
The generic ingredient in SODIUM ZIRCONIUM CYCLOSILICATE is sodium zirconium cyclosilicate. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the sodium zirconium cyclosilicate profile page.
Summary for 217549
| Tradename: | SODIUM ZIRCONIUM CYCLOSILICATE |
| Applicant: | Lupin |
| Ingredient: | sodium zirconium cyclosilicate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | FOR SUSPENSION;ORAL | Strength | 5GM/PACKET | ||||
| Approval Date: | Aug 7, 2026 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | FOR SUSPENSION;ORAL | Strength | 10GM/PACKET | ||||
| Approval Date: | Aug 7, 2026 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
